C
Power Law company profile
CG Oncology
Biotech & Life Sciences · Irvine, United States · Founded 2010 · IPO 2024 Unicorn
Valuation
$4.96B
Market cap · Apr/2026
Revenue
$4.0M
Latest reported FY
Global footprint
Where CG Oncology has talent and traffic
Web traffic by country
11K
monthly visits
across markets
across markets
🇺🇸 United States60.9%
🇮🇳 India19.1%
🇬🇧 United Kingdom11.8%
🇨🇦 Canada6.4%
🇵🇭 Philippines2.7%
Patent intelligence
$9M patent portfolio · 3 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$9M
0.19% of market cap · 14.4× smaller than top peer Deciphera Pharmaceuticals ($133M)
3 active patent families
Where CG Oncology innovates
Cancer researchCell biologyOncolytic virusCell specificOncology
Above peer median on Market · Below peer median on Strategic, Technology
Quality vs same-sector peers
CG Oncology on the five Patsnap quality dimensions
CG Oncology in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where CG Oncology concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across CG Oncology and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee CG Oncology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.